• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

膀胱内卡介苗（BCG）免疫治疗相关肺炎：一例报告

Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy-Related Pneumonitis: A Case Report.

作者信息

Gullu Arslan Nevra, Aksakal Sengul

机构信息

Department of Pulmonary Medicine, Samsun Education and Research Hospital, Samsun, TUR.

Clinic of Alergy and Immunology, Samsun Education and Research Hospital, Samsun, TUR.

出版信息

Cureus. 2025 Aug 28;17(8):e91171. doi: 10.7759/cureus.91171. eCollection 2025 Aug.

DOI:10.7759/cureus.91171
PMID:41018418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12476081/
Abstract

Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is widely used as a standard adjuvant treatment for non-muscle invasive bladder cancer. The exact mechanism of BCG action and the mechanisms responsible for early and late complications after intravesical BCG treatment remain poorly understood, and it is still unclear in which patients local or systemic adverse effects will develop. The patient who received intravesical BCG treatment for six weeks presented with complaints of arthralgia, loss of appetite, fatigue, and intermittent low-grade fever. High-resolution chest computed tomography showed bilateral ground-glass opacities and showed no response to antiviral or antimicrobial treatments. Bronchoalveolar lavage flow cytometry demonstrated a markedly elevated CD4/CD8 ratio (6:1). Based on clinical, radiologic, and immunologic findings, pneumonitis secondary to BCG-related inflammation (BCG-itis) was diagnosed. Differentiating infectious from immune-mediated adverse events in BCG-itis can be challenging.

摘要

膀胱内卡介苗（BCG）免疫疗法被广泛用作非肌肉浸润性膀胱癌的标准辅助治疗方法。BCG作用的确切机制以及膀胱内BCG治疗后早期和晚期并发症的发生机制仍知之甚少，目前仍不清楚哪些患者会出现局部或全身不良反应。接受了六周膀胱内BCG治疗的患者出现关节痛、食欲不振、疲劳和间歇性低热等症状。高分辨率胸部计算机断层扫描显示双侧磨玻璃影，对抗病毒或抗菌治疗无反应。支气管肺泡灌洗流式细胞术显示CD4/CD8比值显著升高（6:1）。根据临床、放射学和免疫学检查结果，诊断为BCG相关炎症继发的肺炎（BCG肺炎）。区分BCG肺炎中的感染性与免疫介导的不良事件可能具有挑战性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e559/12476081/405f1b86f211/cureus-0017-00000091171-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e559/12476081/a56f2d83977a/cureus-0017-00000091171-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e559/12476081/405f1b86f211/cureus-0017-00000091171-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e559/12476081/a56f2d83977a/cureus-0017-00000091171-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e559/12476081/405f1b86f211/cureus-0017-00000091171-i02.jpg

相似文献

1
Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy-Related Pneumonitis: A Case Report.膀胱内卡介苗（BCG）免疫治疗相关肺炎：一例报告
Cureus. 2025 Aug 28;17(8):e91171. doi: 10.7759/cureus.91171. eCollection 2025 Aug.
2
Vesicoureteral Reflux膀胱输尿管反流
3
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.卡介苗联合α干扰素膀胱灌注与单纯卡介苗膀胱灌注治疗非肌层浸润性膀胱癌的比较
Cochrane Database Syst Rev. 2017 Mar 8;3(3):CD012112. doi: 10.1002/14651858.CD012112.pub2.
4
Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer.卡介苗膀胱灌注与丝裂霉素C治疗Ta和T1期膀胱癌的比较
Cochrane Database Syst Rev. 2003(3):CD003231. doi: 10.1002/14651858.CD003231.
5
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.经尿道膀胱内吉西他滨治疗非肌层浸润性膀胱癌（NMIBC）：系统评价。
BJU Int. 2012 Feb;109(4):496-505. doi: 10.1111/j.1464-410X.2011.10880.x.
6
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.使用复发性肿瘤分级来指导卡介苗治疗：低级别复发并非良性。
Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.
7
Intravesical electromotive drug administration for non-muscle invasive bladder cancer.非肌层浸润性膀胱癌的膀胱内电动药物给药
Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD011864. doi: 10.1002/14651858.CD011864.pub2.
8
Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.卡介苗膀胱灌注在降低高危浅表性膀胱癌肿瘤复发方面优于丝裂霉素C：一项随机试验的荟萃分析
BJU Int. 2004 Mar;93(4):485-90. doi: 10.1111/j.1464-410x.2003.04655.x.
9
Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.BCG 与 MMC 联合 COMBAT 或 EMDA 用于治疗中高危非肌层浸润性膀胱癌患者的膀胱内辅助治疗。一项前瞻性研究的结果。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7453-7459. doi: 10.1007/s00432-023-04688-0. Epub 2023 Mar 23.
10
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.卡介苗治疗失败的非肌层浸润性膀胱癌的未满足需求：国际膀胱癌小组的系统评价和成本效益分析
Eur Urol Oncol. 2025 Feb;8(1):216-229. doi: 10.1016/j.euo.2024.10.012. Epub 2024 Nov 15.

本文引用的文献

1
BCG therapy in bladder cancer and its tumor microenvironment interactions.卡介苗治疗膀胱癌及其与肿瘤微环境的相互作用。
Clin Microbiol Rev. 2025 Jun 12;38(2):e0021224. doi: 10.1128/cmr.00212-24. Epub 2025 Mar 20.
2
Complications of Intravesical BCG Immunotherapy for Bladder Cancer.膀胱癌膀胱内卡介苗免疫治疗的并发症。
Radiographics. 2019 Jan-Feb;39(1):80-94. doi: 10.1148/rg.2019180014. Epub 2018 Dec 7.
3
A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer.一种关于膀胱癌膀胱内卡介苗治疗后并发症发病机制的新观点。
Int J Infect Dis. 2018 Jul;72:63-68. doi: 10.1016/j.ijid.2018.05.006. Epub 2018 May 17.
4
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer.肿瘤内Th2倾向与膀胱癌患者对膀胱内卡介苗治疗临床反应中Th1功能表型增加相结合。
Cancer Immunol Immunother. 2017 Apr;66(4):427-440. doi: 10.1007/s00262-016-1945-z. Epub 2016 Dec 22.
5
Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.膀胱内治疗反应的细胞因子检测板（CyPRIT）：尿细胞因子水平变化的列线图预测患者对卡介苗的反应。
Eur Urol. 2016 Feb;69(2):197-200. doi: 10.1016/j.eururo.2015.06.023. Epub 2015 Jun 25.
6
Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.卡介苗（BCG）治疗中高危 Ta、T1 期膀胱乳头状癌的副作用：EORTC 泌尿生殖系统癌症组比较三分之一剂量与全剂量以及 1 年与 3 年维持 BCG 的随机 3 期研究结果。
Eur Urol. 2014 Jan;65(1):69-76. doi: 10.1016/j.eururo.2013.07.021. Epub 2013 Jul 24.
7
The regulatory effects of polyporus polysaccharide on the nuclear factor kappa B signal pathway of bladder cancer cells stimulated by Bacillus Calmette-Guerin.云芝多糖对卡介苗刺激的膀胱癌细胞核因子 κB 信号通路的调控作用。
Chin J Integr Med. 2011 Jul;17(7):531-6. doi: 10.1007/s11655-010-0787-y. Epub 2011 Jul 3.
8
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.膀胱尿路上皮癌及卡介苗诱导的肉芽肿中PD-L1（B7-H1）的表达：与局限性疾病进展的关联
Cancer. 2007 Apr 15;109(8):1499-505. doi: 10.1002/cncr.22588.
9
Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.膀胱内灌注卡介苗能否降低浅表性膀胱癌患者的复发率？一项随机试验的荟萃分析。
Urology. 2006 Jun;67(6):1216-23. doi: 10.1016/j.urology.2005.12.014.
10
Spectrum of bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy.膀胱内卡介苗免疫治疗后卡介苗（BCG）感染谱
Clin Infect Dis. 2003 Jan 15;36(2):140-8. doi: 10.1086/344908. Epub 2003 Jan 3.